Assessment of the Validity of the INR System for Patients with Liver Impairment

M J Kovacs; A Wong; K MacKinnon; K Weir; M Keeney; E Boyle; M Cruickshank

doi:10.1055/s-0038-1642513

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1994; 71(06): 727-730
DOI: 10.1055/s-0038-1642513

Review Article

Schattauer GmbH Stuttgart

Assessment of the Validity of the INR System for Patients with Liver Impairment

Autoren

M J Kovacs

¹The Department of Hematology/Blood Bank, Victoria Hospital, University of Western Ontario, London, Ontario, Canada

³The Department of Medicine, University of Western Ontario, London, Ontario, Canada
A Wong

¹The Department of Hematology/Blood Bank, Victoria Hospital, University of Western Ontario, London, Ontario, Canada

³The Department of Medicine, University of Western Ontario, London, Ontario, Canada
K MacKinnon

¹The Department of Hematology/Blood Bank, Victoria Hospital, University of Western Ontario, London, Ontario, Canada
K Weir

¹The Department of Hematology/Blood Bank, Victoria Hospital, University of Western Ontario, London, Ontario, Canada
M Keeney

¹The Department of Hematology/Blood Bank, Victoria Hospital, University of Western Ontario, London, Ontario, Canada
E Boyle

⁴The Departments of Biostatistics and Epidemiology, University of Western Ontario, London, Ontario, Canada
M Cruickshank

²The Department of Hematology, University Hospital, London, Ontario, Canada

³The Department of Medicine, University of Western Ontario, London, Ontario, Canada

Abstract

als PDF herunterladen

Summary

The INR system was developed to standardize PT reporting in patients on oral anticoagulants. We prospectively collected blood samples from 29 patients with liver impairment (INR 1.5-3.5). Control patients were on warfarin (n = 31). PT’s were measured on an ACL-300 with three thromboplastin reagents. INR’s were calculated using instrument specific ISI’s. Other tests performed were FDP’s, fibrinogen, aPTT, factors II, V, VII and X. The INR’s for each patient in the study population using the three thromboplastin reagents were significantly different (p = 0.0001). Those for the control population were not (p = 0.0658). Fibrinogen, factors V, II and X were different at the 5% level of significance between the populations. FDP’s were detected in 17 study subjects. The INR system is not valid for comparison of patients with liver impairment because different reagents do not give the same INR for the same sample. It is, however, no less valid than the use of PT with different thromboplastin reagents. Further study is recommended.

PDF (415 kb)

Referenzen

References
1 Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-4
2 Hirsh J. Oral anticoagulant drugs. New Engl J Med 1991; 324: 1865-75
3 Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. Arch Intern Med 1992; 152: 278-82
4 Becker DM, Humphries JE, Walker FB, DeMong LK, Bopp JS, Acker MN. Standardizing the prothrombin time: calibrating coagulation instruments as well as thromboplastin. Arch Pathol Lab Med 1993; 117: 602-5
5 Hirsh J. Substandard monitoring of warfarin in North America (editorial). Arch Intern Med 1992; 152: 257-8
6 Triplett DA, Brandt J. International normalized ratios: has their time come (editorial). Arch Pathol Lab Med 1993; 117: 590-2
7 Loeliger EA. ICSH/ICTH Recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Ilacmost 1985; 53: 155-6
8 Ansell JE. Imprecision of prothrombin time monitoring of oral anticoagulation. Am J Clin Pathol 1992; 98: 237-9
9 Ray MJ, Smith IR. The dependence of the international sensitivity index on the coagulomctcr used to perform the prothrombin time. Thromb Haemost 1990; 63: 424-9
10 Chantarangkul V, Tripodi A, Mannucci PM, Bonomi AB. The effect of instrumentation on thromboplastin calibration (letter). Thromb Haemost 1992; 67: 588-9
11 Kirkwood TB L. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. Thromb Haemost 1983; 49: 238-14
12 Loeliger EA, Poller L, Samama M, Thomson JM, Van den Besselaar AM H P, Vermylen J, Verstraete M. Questions and answers on prothrombin time standardization in oral anticoagulant control. Thromb Haemost 1985; 54: 515-7
13 Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51: 479-85
14 Mammen EF. Coagulation abnormalities in liver disease. Hematol Oncol Clin North Am 1992; 6: 1247-57
15 van den Besselaar AM H P. Recommended method for reporting therapeutic control of oral anticoagulant therapy. Thromb Haemostas 1990; 63: 316-7
16 Morrison DF. The analysis of a single sample at repeated measurements. Biometrics 1972; 28: 55-71
17 Shott S. Statistics for Health Professionals. In: Jovanovich Inc. B, ed. Toronto: WB Saunders Company Hancourt; 1990
18 Kovacs MJ, Keeney M, Chin-Yee I. Decreasing liver biopsy complications (letter). Ann Intern Med 1993; 119: 436